Compounds > 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
Page last updated: 2024-12-07

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're asking about a compound called **1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol**. This is a rather complex molecule with a specific structure. Let's break down its features and why it's significant in research.

**Structure and Properties**

* **Nitroimidazole:** The 2-nitro-1-imidazolyl part refers to a nitro group (NO2) attached to an imidazole ring. Nitroimidazoles are known for their ability to interfere with DNA synthesis and repair, making them useful as anti-infective agents.
* **Aziridine:** The 3-aziridino part indicates an aziridine ring, a three-membered ring containing nitrogen. Aziridines are highly reactive due to their ring strain, and they can act as alkylating agents.
* **2-propanol:** This indicates a propanol molecule (a three-carbon alcohol) with a hydroxyl group on the second carbon atom.

**Importance in Research**

This compound's unique combination of features likely makes it of interest for several research areas:

* **Anti-cancer Research:** The nitroimidazole and aziridine components can potentially act as DNA damaging agents, targeting rapidly dividing cancer cells.
* **Anti-infective Research:** Nitroimidazoles are known for their effectiveness against anaerobic bacteria and parasites. This compound could be investigated for its potential in treating various infections.
* **Chemical Biology and Drug Development:** The compound's complex structure provides a starting point for exploring new drug candidates. By modifying its chemical structure, researchers might create compounds with improved potency, selectivity, and pharmacokinetic properties.

**Considerations:**

It's important to note that this compound is likely still under investigation. Its exact mechanisms of action, efficacy, safety, and potential applications may not be fully established yet.

**To find more information:**

* You can search scientific databases like PubMed or Google Scholar using the compound's full name or specific keywords like nitroimidazole, aziridine, or anti-cancer to find relevant research papers.
* You can consult specialized scientific journals that focus on the fields mentioned above (e.g., journals on cancer research, infectious diseases, medicinal chemistry).

By searching for relevant research, you can learn more about this compound's potential applications and significance in scientific research.

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID100153
CHEMBL ID63753
SCHEMBL ID367134
MeSH IDM0123580

Synonyms (20)

Synonym
NCI60_003087
rsu-1069
1-(2-nitro-1-imidazoyl)-3-(1-aziridinyl)-2-propanol
nsc 347503
rsu 1069
1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
brn 4190263
1h-imidazole-1-ethanol, alpha-(1-aziridinylmethyl)-2-nitro-
88876-88-4
nsc-347503
nsc347503
mls003171052 ,
CHEMBL63753
1-(aziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol
smr001874961
SCHEMBL367134
OEWYWFJWBZNJJG-UHFFFAOYSA-N
1-(2-nitro-1-imidazolyl)-3-(1-aziridinyl)-2-propanol
alpha-(1-aziridinylmethyl)-2-nitro-1h-imidazole-1-ethanol
DTXSID301213980

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This result suggests the possibility that a diffusible toxic product may be released from cells."( Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product.
Gulyas, S; Hill, RP; Whitmore, GF, 1989)		0.28
" Such reduced tumor oxygenation would increase the cytotoxic effects of RSU-1069 which is known to be more toxic to cells at reduced oxygen levels."( The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Acker, B; Chaplin, DJ, 1987)		0.27
" In addition, recent experiments suggest that the compound is highly toxic to hypoxic tumor cells in vivo."( Studies on the toxicity of RSU-1069.
Gulyas, S; Whitmore, GF, 1986)		0.27
" The oxygen dependence of the toxic response has not previously been characterized."( Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch, CJ, 1993)		0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Reasoning that this may lie in a more beneficial pharmacokinetic profile, we investigated the plasma pharmacokinetics, tissue distribution and metabolism of RB 6145 in mice using a specially developed reversed-phase HPLC technique."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991)		0.28
" In unclamped tumours, the peak concentration was 50 micrograms g-1 with an elimination t1/2 of 36."( Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.
Koch, CJ; Wallen, CA; Wheeler, KT; Wong, KH, 1991)		0.28
" These studies should provide a pharmacokinetic basis for the evaluation and development of improved mixed-function sensitizers."( Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton, MI; Workman, P, 1988)		0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
"To compare the effect on the RIF-1 murine sarcoma of nine bioreductive agents from five different classes when used in combination with either photodynamic therapy or clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"RIF-1 tumors implanted intradermally in C3H mice were treated with either 50J photodynamic therapy or with 120 min clamping in combination with either misonidazole, pimonidazole, metronidazole, nimorazole, RB6145, RSU1069, SR4233, mitomycin-C, or RB90740."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"RSU1069 produced the greatest anti-tumor activity in combination with both photodynamic therapy and clamping."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29
"Of the bioreductive agents studied RSU1069, RB6145 and mitomycin-C showed the greatest anti-tumor response in combination with photodynamic therapy."( Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Adams, GE; Bradley, JK; Bremner, JC; Naylor, MA; Sansom, JM; Stratford, IJ, 1994)		0.29

Bioavailability

ExcerptReferenceRelevance
" bioavailability of 55%."( Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
Walton, MI; Workman, P, 1988)		0.27

Dosage Studied

ExcerptRelevanceReference
" and oral dosing and possibly contributed to the acute toxicity."( Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
Binger, M; Workman, P, 1991)		0.28
" Maximum tolerated single, intraperitoneal doses (MTD) were determined in C3H/He mice bearing subcutaneous KHT sarcomas, and a drug dose-response relationship for radiosensitization was established for each compound administered at the optimum time (45-60 min) before local irradiation of tumors with a 10-Gy dose of X-rays."( Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Adams, GE; Cole, S; Fielden, EM; Jenkins, TC; Stratford, IJ, 1990)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency10.95230.000811.382244.6684AID686978; AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency14.12540.707912.194339.8107AID720542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID217028The efficiency of radiosensitization is the concentration required to give an SER of 1.6 (in vitro)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID217031Sensitizer enhancement ratio(SER) determined at the maximum nontoxic dose by measuring the number of cells killed at a conc 0.8 nM (in vitro)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID216888IC50 of oxic to that of IC50 of hypoxic was determined in V79 cells; hypoxia selective cytotoxicity.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID18850Plating efficiency of drug treated irradiated tumors relative to irradiated only group1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID233560The ratio of C50(AIR) to that of C50(N2).1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID47690Cytotoxicity in air (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID47688Molar concentration required to give a sensitizer enhancement ratio of 1.6 in hypoxic CHO (V79) cells.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID217042Selective toxicity to hypoxic V79-379A cells was determined in vitro; expressed as concentration required to give enhancement ratio of 1.61992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID110683In vitro concentration of gamma-radiation to give an enhancement ratio of 1.6 in mice when compared to control V79.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID94668In vivo radiosensitization of KHT tumors in mice by administration at a dose of 0.38 mmol/kg intraperitoneally. The optimum time interval between injection and irradiation of tumor was 60 minutes.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID217027Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under hypoxic (Cnitrogen) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID232995Differential toxicity expressed as the ratio of C50 (air) to C50 (nitrogen)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID115159The maximum tolerated dose described as the highest single intraperitoneal dose which did not produce severe or persistent clinical signs or death of the adult non-tumor bearing mice within 24 hours.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID216722Reduction of optical density by 50% compared to controls when assay was performed under nitrogen in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID217026Concentration which reduced survival to 1% following incubation 3 hours with V79 mammalian cells under aerobic (Cair) conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID47691Cytotoxicity in nitrogen (MMT assay).1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of novel electrophilic nitrofuran carboxamides and carboxylates as radiosensitizers and bioreductively activated cytotoxins.
AID231785Ratio of concentration required to kill 50% aerobic V79-379A cells C50(air) to that of concentration required to kill 50% of cells under N2 C50(N2) was determined1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID23274Partition coefficient measured between octanol and 0.05 M NH4PO4 (pH 7.4) using shake-flask method1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID231786Ratio of concentration which reduced V79 cell survival to 1% under aerobic conditions to that of hypoxic conditions1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID133778Maximum tolerated dose was determined for compound administered intraperitoneally in C3H/He mice1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
AID217044Concentration required to kill 50% of aerobic V79-379A cells (in vitro)1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID115133In vivo radiosensitizing activity measured as maximum tolerated dose in mice.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
A new class of analogues of the bifunctional radiosensitizer alpha-(1-aziridinylmethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069): the cycloalkylaziridines.
AID217043Concentration required to kill 50% of V79-379A cells under N2 (in vitro)1992Journal of medicinal chemistry, Sep-18, Volume: 35, Issue:19
2-Nitroimidazole dual-function bioreductive drugs: studies on the effects of regioisomerism and side-chain structural modifications on differential cytotoxicity and radiosensitization by aziridinyl and oxiranyl derivatives.
AID112714The maximum factor by which the cells were sensitized to radiation in mice1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
AID213953Reduction of optical density by 50% compared to controls when assay was performed under air in Hypoxic V79 Cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Synthesis of a series of nitrothiophenes with basic or electrophilic substituents and evaluation as radiosensitizers and as bioreductively activated cytotoxins.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (46.67)18.7374
1990's49 (46.67)18.2507
2000's3 (2.86)29.6817
2010's3 (2.86)24.3611
2020's1 (0.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.33 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (2.73%)5.53%
Reviews6 (5.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other101 (91.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-aminobenzamide
[no description available]		2.3720benzamides;
substituted aniline		EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
amifostine anhydrous
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.		4.8621diamine;
organic thiophosphate		antioxidant;
prodrug;
radiation protective agent
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		2.3720N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
etanidazole
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.		6.7762C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		1.9910aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		1.9910nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		3.4780azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
lomustine
[no description available]		2.8840N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
mechlorethamine
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.		1.9810nitrogen mustard;
organochlorine compound		alkylating agent
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		4.4511C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
ondansetron
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.		1.9810carbazoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		4.4670mitomycinalkylating agent;
antineoplastic agent
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		1.9610pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
glyoxal
[no description available]		1.9610dialdehydeagrochemical;
allergen;
pesticide;
plant growth regulator
aziridine
[no description available]		1.9710azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent		alkylating agent
adamantane
Adamantane: A tricyclo bridged hydrocarbon.		1.9610adamantanes;
polycyclic alkane
phorone
phorone: an industrial solvent; structure		1.9610dialkenyl ketone
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		9.84322C-nitro compound;
imidazoles		antitubercular agent
porfiromycin
Porfiromycin: Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.		1.9810
methionine sulfoximine
methionine sulfoximine : A non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine .		2.3720methionine derivative;
non-proteinogenic alpha-amino acid;
sulfoximide
buthionine sulfoximine
Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.		2.3720diastereoisomeric mixture;
homocysteines;
non-proteinogenic alpha-amino acid;
sulfoximide		EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor;
ferroptosis inducer
nimorazole
Nimorazole: An antitrichomonal agent which is effective either topically or orally and whose urinary metabolites are also trichomonicidal.		4.4511C-nitro compound;
imidazoles
misonidazole
Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.		11.681003
desmethylmisonidazole
[no description available]		4.8521
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		1.9610benzenes;
phenyl acetates
benzonidazole
benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.		5.1431C-nitro compound;
imidazoles;
monocarboxylic acid amide		antiprotozoal drug
pimonidazole
pimonidazole: structure given in first source		7.8372
2,4-diamino-5-adamantyl-6-methylpyrimidine
[no description available]		1.9610
bw 12c79
5-(2-formyl-3-hydroxyphenoxy)pentanoic acid: aromatic aldehyde; aldehyde group interacts with N-terminal amino group of both alpha-globin chains		1.9710
tretazicar
tretazicar: minor descriptor (75-84); on-line & Index Medicus search AZIRIDINES (75-84)		3.0750
rsu 1131
RSU 1131: structure given in first source		3.0750
aluminum phthalocyanine
aluminum phthalocyanine: the aluminum phthalocyanine can be sulfonated to different degrees; see also record for aluminum tetrasulfophthalocyanine		1.9810organic molecular entity
1-(2-nitro-1-imidazoly)-3-(2,3-dimethylaziridino)-2-propanol
[no description available]		3.5890
rb 88716
RB 88716: structure given in first source		3.2360
rb 6145
RB 6145: structure given in first source; prodrug to RSU 1069; PD 144872 is the R-enantiomer of RB 6145		5.89190
rsu 1172
[no description available]		1.9610
rb 7040
[no description available]		3.2260
3,4-dihydro-5-methyl-1(2h)-isoquinolinone
3,4-dihydro-5-methyl-1(2H)-isoquinolinone: structure given in first source		1.9810isoquinolines
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.6630L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		1.98102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
diethyl maleate
diethyl maleate : A maleate ester resulting from the formal condensation of both carboxy groups of maleic acid with ethanol. A colourless liquid at room temperature (m.p. -10degreeC) with boiling point 220degreeC at 1 atm., it is commonly used as a dienophile for Diels-Alder-type cycloaddition reactions in organic synthesis.		1.9610ethyl ester;
maleate ester		glutathione depleting agent
phosphorus
Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.		1.9810monoatomic phosphorus;
nonmetal atom;
pnictogen		macronutrient
apaziquone
apaziquone: structure given in first source; RN given refers to (E)-isomer		3.7730indoles
s72055
S72055: RN given refers to parent cpd		1.9810
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9610organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
hoe 33342
bisbenzimide ethoxide trihydrochloride: benzimidazole fluorescent dye		1.9710
deoxyguanosine
[no description available]		1.9610purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2'-deoxyguanosine 5'-phosphate
2'-deoxyguanosine 5'-phosphate: RN given refers to parent cpd.. 2'-deoxyguanosine 5'-monophosphate : A purine 2'-deoxyribonucleoside 5'-monophosphate having guanine as the nucleobase.		1.9610deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-monophosphate		Escherichia coli metabolite;
mouse metabolite
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		5.94140aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
phosphorus radioisotopes
Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Fibrosarcoma
A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)		03.0850
EHS Tumor
[description not available]		03.84120
Experimental Neoplasms
[description not available]		07.85171
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Benign Neoplasms
[description not available]		07.1162
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		07.1162
Carcinoma, Epidermoid
[description not available]		02.6830
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.6830
Experimental Hepatoma
[description not available]		01.9810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9910
Angiogenesis, Pathologic
[description not available]		01.9910
Anoxemia
[description not available]		02.6830
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.6830
Breast Cancer
[description not available]		01.9910
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9910
Carcinoma, Anaplastic
[description not available]		02.420
Cancer of Cervix
[description not available]		02.0110
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		02.420
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0110
Sarcoma, Epithelioid
[description not available]		02.3720
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.3720
Emesis
[description not available]		03.7621
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.7621
Leukemia L 1210
[description not available]		01.9810
Electrolytes
Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)		01.9810
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		02.8940
Cancer, Second Primary
[description not available]		01.9810
Experimental Mammary Neoplasms
[description not available]		02.3820
Cancer of Lung
[description not available]		03.2260
Lung Neoplasms
Tumors or cancer of the LUNG.		03.2260
Malignant Melanoma
[description not available]		02.8840
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.8840
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Cancer of Colon
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9710
Metastase
[description not available]		01.9710
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		01.9710
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3511